Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. (NY: OGN )

18.10 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Organon & Co.

< Previous 1 2 3 4 5 6 Next >
ObsEva Stock Surges On Potential $500M Ebopiprant Deal For Preterm Labor
Organon & Co (NYSE: OGN) will license the global development, manufacturing, and commercial rights to ObsEva SA's (NASDAQ: OBSV) ebopiprant (OBE022)... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021
Upgrades Craig-Hallum upgraded the previous rating for Lindblad Expeditions Holdings Inc (NAS... 
Via Benzinga
Joblessness Surprise
Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021
Upgrades According to Stephens & Co., the prior rating for World Acceptance Corp (NASDAQ:... 
Via Benzinga
Why Ocugen Shares Are Rallying Today
Ocugen, Inc. (NASDAQ: OCGN) shares were advancing strongly Thursday after the biopharma issued a regulatory update. Pennsylvania-based Ocugen said it has initiated a rolling... 
Via Benzinga
3 Stocks I'd Avoid at All Costs
On the surface, these companies seem like underpriced investments, but look a little closer and there's a good reason to stay away. 
Via The Motley Fool
Stay Away From Low-Growth Organon
Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive. 
Via InvestorPlace
Summer Friday
The stock market tried for another record after yesterday's late blowout over the infrastructure deal. 
Via Talk Markets
Don’t Miss the Opportunity Presented by Organon Stock
If a company's spun off from a pharmaceutical giant, you'd think the buzz about it would be deafening. Yet OGN stock remains an underappreciated gem. 
Via InvestorPlace
Reconsidered Boom
The US markets tried to repeat the big rise from yesterday, and appears to have succeeded. 
Via Talk Markets
Motivation Really Matters When It Comes to Organon
Though spun-off entities can perform very well, with OGN stock, you should assess which company is getting the better deal. 
Via InvestorPlace
Continued Uncertainty
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
Dreary Day
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
Unheeding Markets
Today oil prices rose over $70. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2021
Upgrades According to Argus Research, the prior rating for Zoom Video Communications Inc (NASDAQ:ZM) was changed from Hold to Buy. Zoom Video Communications earned $1.32... 
Via Benzinga
Juvenile Investing Mob
Tech stocks did well in Europe but not in the US. The data are unconvincing. 
Via Talk Markets
FDA surprise
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
Exposures Product Safety
Merck Completes Women's Health Organon Spinoff
In a move to free up a cash windfall and streamline the business, Merck & Co Inc (NYSE: MRK) had long planned to slice away its women’s health business into a... 
Via Benzinga
Inside Merck's Organon Spinoff And Why It Could Be Worth Billions
Don't think of Merck spinoff Organon as a research engine. The new pharmaceutical stock — which begins active trading on Thursday — is a commercial entity. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.